NMP22 test kit data

The assay showed 100 percent sensitivity in patients found to have invasive disease in a study to predict disease status in 90 patients who had had surgery for bladder cancer. As reported in the Journal of Urology, the urinary NMP22 tumor marker, detected by the NMP22 test kit, was measured after transurethral resection of the transitional cell carcinoma. Urine samples for analysis were collected 5 to 60 days after surgery. Disease status was determined three to six months later by cystoscopy. All 6 patients with invasive disease at the time of that exam were identified by the assay. ...